Drug Trial Radar · NCT06847321
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Feb 17, 2025
Primary completion
Jan 31, 2029
Study completion Mar 15, 2029
Sponsor
- Lead sponsor
- Lighthouse Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P. gingivalis bacterium, to potentially help to halt or slow down the progression of AD and its symptoms. A saliva test will be done to determine P. gingivalis infection. Tests for AD include standard questionnaires such as MMSE and a blood test for pTau217. Treatment will be blinded, meaning the participant and the doctor will not know if the participant is receiving LHP588 or placebo. The total time for participation in the study may be up to 64 weeks. This includes a screening period (to ensure the participant is suitable for the study and the study is suitable for the participant) of up to 12 weeks, a treatment period of up to 48 weeks, and a safety follow-up period of 4 weeks after the last dose of the study drug to check the participant's overall health. Treatment is a once-a-day capsule. Caregiver participation is required. The study requires the participant to visit the study center (with the caregiver) at least 20 times within 64 weeks (this does not include any unplanned visits that may be recommended by the study doctor). In addition, the study doctor or clinic staff will contact the participant via phone at least 1 time.
Conditions
- Alzheimer Disease
- Alzheimer Disease Due to P. Gingivalis
Interventions
LHP588Drug
25 mg, once daily
LHP588Drug
50 mg, once daily
Placebo DrugDrug
Placebo, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in ADAS-Cog11Time frame: 40 - 48 weeks
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Banner Alzheimer's Institute
Phoenix, Arizona · Recruiting
Barrow Neurological Institute
Phoenix, Arizona · Recruiting
Clinical Endpoints
Scottsdale, Arizona · Recruiting
Esperanza Clinical
Murrieta, California · Recruiting
Oakland Clinical Research
Oakland, California · Recruiting
ATP Clinical Research, Inc.
Orange, California · Recruiting
Riverside Clinical Research
Riverside, California · Recruiting
CenExel Sherman Oaks
Sherman Oaks, California · Recruiting
CenExel Denver, CO
Englewood, Colorado · Recruiting
JEM Research Institute
Atlantis, Florida · Recruiting
Brain Matters Research
Delray Beach, Florida · Recruiting
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida · Recruiting
Conquest Research - Lake Nona
Orlando, Florida · Recruiting
Anchor Neuroscience
Pensacola, Florida · Active not recruiting
Progressive Medical Research
Port Orange, Florida · Recruiting
Alzheimer's Research and Treatment Center - Stuart
Stuart, Florida · Recruiting
Alzheimer's Research and Treatment Center - Wellington
Wellington, Florida · Recruiting
Columbus Memory Center
Columbus, Georgia · Recruiting
Center for Advanced Research & Education Flourish-Gainesville
Gainsville, Georgia · Recruiting
Ascension via Christi Research
Wichita, Kansas · Recruiting
Tandem Clinical Research - Metairie
Metairie, Louisiana · Recruiting
Headlands PharmaSite
Pikesville, Maryland · Recruiting
Adams Clinical Boston
Boston, Massachusetts · Recruiting
Headlands Research-EMA
Plymouth, Massachusetts · Recruiting
Adams Clinical Watertown
Watertown, Massachusetts · Recruiting
Neurological Research Center - Hattiesburg Clinic
Hattiesburg, Mississippi · Recruiting
Clinical Research Professionals - Headlands
Chesterfield, Missouri · Recruiting
CenExel Research - Toms River
Toms River, New Jersey · Recruiting
IMA Evaluations
Albuquerque, New Mexico · Recruiting
Alzheimer's Disease Research Center
Albany, New York · Recruiting
Adams Clinic Harlem
New York, New York · Recruiting
NDx Clinical Research
Dayton, Ohio · Recruiting
Summitt Research
Portland, Oregon · Recruiting
K2 Medical Research Nashville LLC
Nashville, Tennessee · Recruiting
Kerwin Research Center, LLC - Oak Cliff
Dallas, Texas · Recruiting
Kerwin Research Center, LLC in Texas
Dallas, Texas · Recruiting
University of Virginia Adult Neurology
Charlottesville, Virginia · Recruiting
Re-Cognition Health Fairfax
Fairfax, Virginia · Active not recruiting
Northwest Clinical Research Center
Bellevue, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.